Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Shares Outstanding (Weighted Average): 2014-2024

Historic Shares Outstanding (Weighted Average) for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to $111.4 million.

  • Viking Therapeutics' Shares Outstanding (Weighted Average) rose 1.49% to $112.4 million in Q3 2025 from the same period last year, while for Sep 2018 it was $60.7 million, marking a year-over-year increase of 119.00%. This contributed to the annual value of $111.4 million for FY2024, which is 11.40% up from last year.
  • As of FY2024, Viking Therapeutics' Shares Outstanding (Weighted Average) stood at $111.4 million, which was up 11.40% from $100.0 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $111.4 million in FY2024 and a low of $73.0 million during FY2020.
  • For the 3-year period, Viking Therapeutics' Shares Outstanding (Weighted Average) averaged around $96.1 million, with its median value being $100.0 million (2023).
  • Per our database at Business Quant, Viking Therapeutics' Shares Outstanding (Weighted Average) fell by 1.98% in 2022 and then spiked by 30.44% in 2023.
  • Over the past 5 years, Viking Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $73.0 million in 2020, then grew by 7.24% to $78.2 million in 2021, then declined by 1.98% to $76.7 million in 2022, then spiked by 30.44% to $100.0 million in 2023, then increased by 11.40% to $111.4 million in 2024.